{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:19:20Z","timestamp":1790626760204,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>Human epididymis protein 4 (HE4), a precursor of human epididymis protein, has been proposed as a tumor marker for ovarian cancer. We evaluated HE4 in comparison with cancer antigen 125 (CA 125) in healthy individuals and in patients with benign and malignant diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>CA 125 and HE4 serum concentrations were determined in 101 healthy individuals, 535 patients with benign pathologies (292 with benign gynecologic diseases) and 423 patients with malignant diseases (127 with ovarian cancers). CA 125 and HE4 cutoffs were 35 kU\/L and 140 pmol\/L, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>HE4 and CA 125 results were abnormal in 1.1% and 9.9% of healthy individuals and in 12.3% and 37% of patients with benign diseases, respectively. Renal failure was the most common cause of increased HE4 in patients with benign disease, who had significantly higher HE4 concentrations (P = 0.001) than patients with other benign diseases. HE4 showed a higher specificity than CA 125 in patients with benign gynecologic diseases, with abnormal concentrations in 1.3% and 33.2% of the patients, respectively. HE-4 concentrations were abnormal primarily in gynecologic cancer and lung cancer. By contrast, CA 125 was increased in many different nonovarian malignancies, including nonepithelial tumors. A significantly higher area under the ROC curve was obtained with HE4 than with CA 125 for differentiating benign from malignant diseases (0.755 vs 0.643) and in the differential diagnosis of gynecologic diseases (0.874 vs 0.722).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>HE4 has significantly higher diagnostic specificity than CA 125, and the combination of CA 125 and HE4 improved the detection of ovarian cancer in all stages and histological types.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2010.157073","type":"journal-article","created":{"date-parts":[[2011,9,21]],"date-time":"2011-09-21T02:38:29Z","timestamp":1316572709000},"page":"1534-1544","source":"Crossref","is-referenced-by-count":161,"title":["Comparison of Serum Human Epididymis Protein 4 with Cancer Antigen 125 as a Tumor Marker in Patients with Malignant and Nonmalignant Diseases"],"prefix":"10.1093","volume":"57","author":[{"given":"Jose M","family":"Escudero","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Biochemistry (Unit for Cancer Research) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Auge","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Biochemistry (Unit for Cancer Research) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Filella","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Biochemistry (Unit for Cancer Research) and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aureli","family":"Torne","sequence":"first","affiliation":[{"name":"Department of Gynaecology Hospital Cl\u00ednic, Medical School, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Pahisa","sequence":"first","affiliation":[{"name":"Department of Gynaecology Hospital Cl\u00ednic, Medical School, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Molina","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Biochemistry (Unit for Cancer Research) and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,11,1]]},"reference":[{"key":"2020022704532448200_B1","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1016\/S0020-7292(06)60040-4","article-title":"Quality of life considerations in gynecologic cancer. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Penson","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"2020022704532448200_B2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol Cell Proteomics"},{"key":"2020022704532448200_B3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1525-1438.2005.00441.x","article-title":"New tumor markers: CA125 and beyond","volume":"15","author":"Bast","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"2020022704532448200_B4","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","article-title":"National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers","volume":"54","author":"Sturgeon","year":"2008","journal-title":"Clin Chem"},{"key":"2020022704532448200_B5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000217776","article-title":"A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas","volume":"13","author":"Molina","year":"1992","journal-title":"Tumour Biol"},{"key":"2020022704532448200_B6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","article-title":"Potential markers that complement expression of CA125 in epithelial ovarian cancer","volume":"99","author":"Rosen","year":"2005","journal-title":"Gynecol Oncol"},{"key":"2020022704532448200_B7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol Oncol"},{"key":"2020022704532448200_B8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","article-title":"The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass","volume":"108","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"},{"key":"2020022704532448200_B9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","article-title":"CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"2020022704532448200_B10","first-page":"558","article-title":"Serum cancer antigen 125 in patients with pleural effusions","volume":"61","author":"How","year":"2006","journal-title":"Med J Malaysia"},{"key":"2020022704532448200_B11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000224628","article-title":"Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology","volume":"30","author":"Molina","year":"2009","journal-title":"Tumour Biol"},{"key":"2020022704532448200_B12","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0028-2243(85)90130-3","article-title":"Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma","volume":"19","author":"Bast","year":"1985","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2020022704532448200_B13","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/37.8.1379","article-title":"Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases","volume":"37","author":"Molina","year":"1991","journal-title":"Clin Chem"},{"key":"2020022704532448200_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000071198","article-title":"How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma","volume":"65","author":"Sevinc","year":"2003","journal-title":"Oncology"},{"key":"2020022704532448200_B15","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000081392","article-title":"Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions","volume":"25","author":"Trape","year":"2004","journal-title":"Tumour Biol"},{"key":"2020022704532448200_B16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13277-010-0049-1","article-title":"Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"key":"2020022704532448200_B17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajog.2010.03.043","article-title":"Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass","volume":"203","author":"Moore","year":"2010","journal-title":"Am J Obstet Gynecol"},{"key":"2020022704532448200_B18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","article-title":"Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass","volume":"117","author":"Nolen","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2020022704532448200_B19","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res"},{"key":"2020022704532448200_B20","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod Pathol"},{"key":"2020022704532448200_B21","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/sj.onc.1205363","article-title":"The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms","volume":"21","author":"Bingle","year":"2002","journal-title":"Oncogene"},{"key":"2020022704532448200_B22","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res"},{"key":"2020022704532448200_B23","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1471-0528.1989.tb03341.x","article-title":"Revised FIGO staging for gynaecological cancer","volume":"96","author":"Shepherd","year":"1989","journal-title":"Br J Obstet Gynaecol"},{"key":"2020022704532448200_B24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1373\/49.3.433","article-title":"Comparison of eight computer programs for receiver-operating characteristic analysis","volume":"49","author":"Stephan","year":"2003","journal-title":"Clin Chem"},{"key":"2020022704532448200_B25","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ajog.2005.05.005","article-title":"Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial","volume":"193","author":"Buys","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"2020022704532448200_B26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0002-9378(84)90035-8","article-title":"Monitoring human ovarian carcinoma with a combination of CA 125, CA 19\u20139, and carcinoembryonic antigen","volume":"149","author":"Bast","year":"1984","journal-title":"Am J Obstet Gynecol"},{"key":"2020022704532448200_B27","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6605119","article-title":"Usefulness of serum HE4 in endometriotic cysts","volume":"101","author":"Montagnana","year":"2009","journal-title":"Br J Cancer"},{"key":"2020022704532448200_B28","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/44.7.1379","article-title":"CA 125 in ovarian cancer: advances and controversy","volume":"44","author":"Fritsche","year":"1998","journal-title":"Clin Chem"},{"key":"2020022704532448200_B29","first-page":"609","article-title":"Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up","volume":"30","author":"van Dalen","year":"2009","journal-title":"Eur J Gynaecol Oncol"},{"key":"2020022704532448200_B30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00003081-200609000-00004","article-title":"Screening for ovarian cancer","volume":"49","author":"Rosenthal","year":"2006","journal-title":"Clin Obstet Gynecol"},{"key":"2020022704532448200_B31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.canlet.2010.03.013","article-title":"Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms","volume":"296","author":"Hellstrom","year":"2010","journal-title":"Cancer Lett"},{"key":"2020022704532448200_B32","first-page":"1773","article-title":"Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21\u20131 and NSE in patients with lung cancer","volume":"25","author":"Molina","year":"2005","journal-title":"Anticancer Res"},{"key":"2020022704532448200_B33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-0-387-68969-2_2","article-title":"SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and\/or each other","volume":"622","author":"Hellstrom","year":"2008","journal-title":"Adv Exp Med Biol"},{"key":"2020022704532448200_B34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000048687","article-title":"S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function","volume":"23","author":"Molina","year":"2002","journal-title":"Tumour Biol"},{"key":"2020022704532448200_B35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: a new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumour Biol"},{"key":"2020022704532448200_B36","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts","volume":"100","author":"Huhtinen","year":"2009","journal-title":"Br J Cancer"},{"key":"2020022704532448200_B37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","article-title":"The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass","volume":"23","author":"Montagnana","year":"2009","journal-title":"J Clin Lab Anal"},{"key":"2020022704532448200_B38","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/1097-0142(19891015)64:8<1652::AID-CNCR2820640816>3.0.CO;2-M","article-title":"Elevated levels of squamous cell carcinoma antigen in patients with a benign disease of the skin","volume":"64","author":"Duk","year":"1989","journal-title":"Cancer"},{"key":"2020022704532448200_B39","first-page":"717","article-title":"Proposed reference value of the CA 125 tumour marker in men","volume":"41","author":"Barcelo","year":"2008","journal-title":"Potential applications in clinical practice. Clin Biochem"},{"key":"2020022704532448200_B40","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","article-title":"Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus","volume":"110","author":"Moore","year":"2008","journal-title":"Gynecol Oncol"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/57\/11\/1534\/32655290\/clinchem1534.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/57\/11\/1534\/32655290\/clinchem1534.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T09:56:19Z","timestamp":1582797379000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/57\/11\/1534\/5621183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,1]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2011,11,1]]},"published-print":{"date-parts":[[2011,11,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2010.157073","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,11,1]]},"published":{"date-parts":[[2011,11,1]]}}}